Welcome to our dedicated page for Prelude Therapeutics SEC filings (Ticker: PRLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing loaded with clinical data tables and dilution clauses can feel impossible. Prelude Therapeutics’ precision-oncology focus means every 10-K includes pages on SMARCA2 degrader chemistry, while each 8-K may reveal pivotal trial readouts that move the stock overnight. If you have ever hunted for cash-runway details or wondered whether a secondary offering is hiding in the footnotes, you know how complex Prelude’s disclosures can be.
Stock Titan turns that complexity into clarity. Our AI-powered summaries flag R&D spending spikes, translate technical risk factors, and surface Prelude Therapeutics SEC filings explained simply. Need the latest Prelude Therapeutics quarterly earnings report 10-Q filing or a concise view of revenue, burn rate and trial costs? It’s here, updated in real time as documents hit EDGAR. Track Prelude Therapeutics insider trading Form 4 transactions and receive Prelude Therapeutics Form 4 insider transactions real-time alerts before the market reacts. You’ll also find the full spectrum of documents—10-K, 10-Q, 8-K, S-3, S-8 and proxy materials—each with an AI summary that highlights what matters.
Looking for actionable insights? Compare segments with our Prelude Therapeutics earnings report filing analysis. Review executive pay in the Prelude Therapeutics proxy statement executive compensation section, or see confidence signals via Prelude Therapeutics executive stock transactions Form 4. We even decode material news with Prelude Therapeutics 8-K material events explained and offer a Prelude Therapeutics annual report 10-K simplified readout so you can spot clinical milestones, partnership terms and dilution risks in minutes—not hours.
GCL Global Holdings Ltd ("GCL") has filed Prospectus Supplement No. 8 and a Form 6-K to disclose a new warrant issuance linked to an existing SG$5 million credit facility extended to its wholly-owned subsidiary, Epicsoft Asia Pte. Ltd.
- Financing context: The facility, arranged with Oversea-Chinese Banking Corporation (OCBC) on 1 Oct 2024 and amended 12 Mar 2025, provides up to SG$5 million (≈ US$3.75 million). One condition precedent for draw-down is issuance of a warrant to OCBC.
- Warrant terms: • Shares underlying warrant: 899,281 ordinary shares • Exercise price: US$4.17 per share • Aggregate exercise proceeds: US$3.75 million • Term: 5 years from 7 Jul 2025 • Automatic exercise triggers if (i) VWAP > US$12 for 20 consecutive trading days, (ii) ≥ 1 million average daily volume, (iii) market cap ≥ US$1 billion, and (iv) an effective resale registration statement is available.
- Use of proceeds: All exercise proceeds will first repay outstanding amounts under the OCBC facility; any excess is earmarked for the subsidiary’s working capital.
- Dilution & registration: The warrant represents potential dilution of ~899k shares (≈ 1.1% of the 83.5 million shares covered by the broader resale prospectus). GCL must file a resale registration statement for these warrant shares within six months (by 7 Jan 2026).
- Listing & compliance: Shares are listed on Nasdaq Global Select Market; GCL commits to maintain listing, register shares, and provide customary registration rights, indemnities and adjustment mechanisms.
The filing primarily informs investors of incremental potential dilution, outlines the company’s obligations to register the warrant shares, and clarifies that any cash from warrant exercise will reduce debt associated with the SG$5 million facility. No new earnings or operational metrics are provided.
FAQ
What is the current stock price of Prelude Therapeutics (PRLD)?
What is the market cap of Prelude Therapeutics (PRLD)?
What is the core focus of Prelude Therapeutics?
Which therapeutic areas does the company target?
What are SMARCA2 degraders and why are they important?
How does Prelude Therapeutics generate revenue and value?
What sets Prelude Therapeutics apart from its competitors?
What role do strategic partnerships play in the company’s development?
How does the company ensure its clinical trials are robust?
Why is targeted protein degradation significant in cancer treatment?
